CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer

Fourteen patients with advanced carcinoma of the breast were treated with CAP combination therapy. An objective therapeutic response (partial remissions with a mean duration of 6.3 months) was achieved in 6 of 13 evaluated patients. This response was observed in soft tissue metastases. Nausea and vomiting were found to be the most frequent undesirable side effects in all patients and could not be avoided by administration of antiemetics. In 2 patients mild nephrotoxicity was found without any effects on further therapy. The results of this study were considered as promising; a definitive assessment of the CAP regimen is expected to come from a randomized study which started in the CMEA countries in 1983.